Endocrine malignancies are rare tumours that are derived from endocrine cells located throughout the body. They encompass a heterogeneous group of malignancies, derived from different endocrine and neuroendocrine cells and have different clinically. The majority of endocrine neoplasms are benign, where the potential for invasion or metastasis is very low. Nevertheless, there is a group of endocrine neoplasms with malignant potential, and thus come under the management of medical oncology, often requiring systemic therapy. These include neuroendocrine tumours, anaplastic and medullary thyroid carcinomas, pheochromocytomas or paragangliomas, and adrenocortical carcinomas. While surgery continues to play a seminal role, the management of advanced endocrine neoplasia is more complex due to their rarity and heterogeneity. This book discusses the use of targeted therapy in the treatment of solid tumours and hematologic malignancies.
Introduction; Therapeutic Agents & Approaches in the Age of Personalized Cancer Care; Optimizing the Development of Targeted Therapies in the Phase I Clinical Trial Setting; Targeted Therapy for Chronic Myeloid Leukemia; Targeted Therapy in the Treatment of Lymphocytic Leukemia; Targeted Therapy in Acute Myeloid Leukemia & Myelodysplastic Syndromes; Targeted Strategies for Multiple Myeloma; Targeted Therapy for Breast Cancer (Ricardo H. Álvarez & Vicente Valero); Targeted Therapy in Gastrointestinal Carcinomas; Targeted Genitourinary cancers; Therapy in Head & Neck Malignancies; Therapeutic Approaches for Ovarian Cancer; Targeted Therapy for Endocrine Neoplasms; Tumors of the Central Nervous System; Targeting Tumors & Personalizing Individual Treatments for Radiation Therapy; Index.
Comments (0)
Your review appreciation cannot be sent
Report comment
Are you sure that you want to report this comment?
Report sent
Your report has been submitted and will be considered by a moderator.